Landmark Trial Shows Two Years of Myeloma Maintenance Therapy Is As Effective As Indefinite Treatment

For patients diagnosed with multiple myeloma, surviving the initial onslaught of the disease is only the first hurdle. The second is the grueling marathon of maintenance therapy—a lower-intensity, but relentless regimen of chemotherapy designed to keep the cancer from returning. For years, the standard medical advice has been to stay on these drugs indefinitely, operating under the assumption that more treatment inevitably yields better survival. But that paradigm is now shifting.[1][2]

A landmark study published on July 15, 2026, in the New England Journal of Medicine has fundamentally challenged the "more is better" dogma in cancer care. The phase III ENDURANCE trial, led by the ECOG-ACRIN Cancer Research Group, revealed that for a specific group of myeloma patients, stopping maintenance therapy after exactly two years is just as effective as continuing it for the rest of their lives.[1][2]

The findings are poised to rewrite clinical guidelines and offer profound psychological relief to thousands of patients. By proving that a fixed-duration approach does not compromise overall survival, oncologists can now confidently give patients an "end date" to their treatment, drastically reducing cumulative side effects and the crushing financial toxicity associated with long-term cancer drugs.[3][5]

Multiple myeloma is a complex cancer of the plasma cells—white blood cells in the bone marrow that normally produce antibodies to fight infection. When these cells become malignant, they multiply uncontrollably, crowding out healthy blood cells and causing bone damage, kidney failure, and immune suppression. While the disease remains technically incurable, modern medicine has transformed it into a highly manageable chronic condition for many.[3]

The cornerstone of this long-term management is lenalidomide, sold under the brand name Revlimid. Lenalidomide is an immunomodulatory drug that works by altering the immune system's microenvironment, making it hostile to myeloma cells while starving tumors of their blood supply. Because it is so effective at suppressing residual disease, clinical practice drifted toward prescribing it continuously until the disease eventually progressed or the patient could no longer tolerate the toxicity.[4][5]

To test whether this indefinite exposure was truly necessary, the ENDURANCE trial enrolled 516 patients with newly diagnosed, standard-risk multiple myeloma. Crucially, these were patients who had completed their initial induction therapy but were not candidates for an upfront autologous stem cell transplant. Researchers randomized the participants into two groups: one that would receive lenalidomide indefinitely, and another that would stop the drug after exactly 24 months.[1][2]

After a median follow-up of nearly seven years, the survival curves of the two groups were virtually indistinguishable. The overall survival rate was 69.0% for the continuous treatment group and 68.6% for the fixed-duration group. Statistically, the extra years of chemotherapy provided zero additional life extension.[4][6]

"The results of this trial are paradigm-shifting, given the current practice of continuous therapy until progression," said Dr. Shaji K. Kumar, a hematologist at the Mayo Clinic, co-chair of the ECOG-ACRIN Myeloma Committee, and lead author of the study. He noted that the data should pave the way for future trial designs to incorporate a defined duration of treatment for the majority of myeloma patients.[2][5]

While the survival benefits were identical, the physical toll was not. Patients in the continuous therapy arm experienced significantly higher rates of adverse events. Grade 3 or higher nonhematologic side effects—which include severe fatigue, debilitating diarrhea, and dangerous infections—occurred in 48.2% of the continuous group, compared to just 31.5% of those who stopped at two years.[4][6]

Prolonged exposure to lenalidomide also carries a dark irony: the treatment meant to hold one cancer at bay can occasionally trigger another. The ENDURANCE trial found that the cumulative incidence of second primary cancers, excluding nonmelanoma skin cancer, was 11.2% in the indefinite group, compared to 8.3% in the fixed-duration group. By stopping at two years, patients meaningfully reduced their risk of developing a completely new malignancy.[1][4]

The psychological burden of indefinite therapy is often underestimated in clinical settings. Yelak Biru, a multiple myeloma survivor and member of ECOG-ACRIN, emphasized that maintenance therapy is not just another medication—it dictates the rhythm of a patient's everyday life. The constant low-grade nausea, the chronic fatigue, and the anxiety of monthly blood draws take a heavy toll. Having the empirical evidence to safely stop treatment allows patients to reclaim their bodies and their routines.[2][3]

There is also a staggering economic dimension to the ENDURANCE findings. Lenalidomide is one of the most expensive oral oncology drugs on the market, often carrying a list price exceeding $20,000 per month in the United States. Trimming years off a patient's prescription not only saves the healthcare system millions of dollars per patient but also rescues families from the compounding copays and out-of-pocket costs that define financial toxicity in modern cancer care.[5][6]

In an editorial accompanying the New England Journal of Medicine publication, Dr. Hira Mian of McMaster University and Dr. Luciano J. Costa of the University of Alabama at Birmingham reflected on the cultural shift this trial represents. They pointed out that the default practice in oncology has long been driven by the anxiety that stopping therapy will invite a relapse. The ENDURANCE trial provides the rigorous, randomized data needed to break that habit and embrace treatment de-escalation.[1][4]

However, the researchers are careful to outline the boundaries of these findings. The trial specifically looked at patients with standard-risk disease who did not undergo an initial stem cell transplant and who received a three-drug induction regimen. It remains uncertain whether patients with high-risk genetic mutations, or those receiving newer four-drug induction regimens, can safely stop maintenance at the two-year mark.[4][5]

Still, the editorial authors argue that the biological principle likely holds true across broader populations. If two years of maintenance is sufficient after a standard three-drug induction, it is highly plausible that continued exposure beyond two years is equally futile for patients who receive even more aggressive, highly effective upfront treatments.[4]

The future of multiple myeloma care is rapidly moving toward personalization, where the duration of therapy is dictated by highly sensitive blood tests rather than a calendar. Oncologists are increasingly using measurable residual disease (MRD) assays—tests capable of detecting a single cancer cell among a million healthy ones—to determine exactly when a patient's body is clear of the disease, allowing for even more precise stopping points.[3][6]

Until those MRD-guided strategies become universally standardized, the ENDURANCE trial offers an immediate, evidence-based off-ramp for thousands of patients. It is a rare and profound victory in oncology: a moment where doing less not only spares patients from unnecessary suffering but proves to be exactly as effective as doing more.[1][2]